Acurx Pharmaceuticals, Inc. (ACXP) Stock Forecast
ACXP analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 3 analysts
- Price target
- $17.00 average of analyst targets
- Upside to target
- +1,445.5% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.45
- 52-week range
- $1.10 – $7.01
ACXP analyst ratings
3 analystsNumber of analysts at each rating.
ACXP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ACXP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.42 | −$0.45 | −$0.40 | −$1.23 | +65.5% | 2 |
| Current fiscal year (2026) | −$1.93 | −$2.00 | −$1.85 | −$5.32 | +63.8% | 2 |
| Next fiscal year (2027) | −$1.75 | −$1.90 | −$1.60 | −$1.93 | +9.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ACXP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
ACXP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ACXP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.46 | −$0.46 | −$0.42 | −$0.42 | −$0.42 | −6.6% | 2 up · 0 down |
| Current fiscal year (2026) | −$1.97 | −$1.97 | −$1.93 | −$1.93 | −$1.93 | −2.3% | 1 up · 1 down |
| Next fiscal year (2027) | −$2.13 | −$2.13 | −$1.75 | −$1.75 | −$1.75 | −17.8% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ACXP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ACXP beat in 9 of 12.
What analysts expect from ACXP
3 analysts cover Acurx Pharmaceuticals; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.00, 1,445.5% above the latest close of $1.10. Analysts expect earnings of −$1.93 per share for 2026, +63.8% from a year earlier. For 2027 the average estimate is −$1.75 per share. Acurx Pharmaceuticals beat the EPS estimate in 9 of the last 12 quarters.
Related: ACXP income statement, ACXP key metrics, ACXP chart. See the ACXP stock overview for the latest quote and news.
ACXP forecast FAQ
What is Acurx Pharmaceuticals's price target?
The average analyst price target for Acurx Pharmaceuticals is $17.00, 1,445.5% above the latest close of $1.10.
Is Acurx Pharmaceuticals a buy, hold or sell?
Of 3 analysts covering Acurx Pharmaceuticals, 2 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Acurx Pharmaceuticals's EPS forecast?
Analysts forecast −$1.93 per share for 2026 (range −$2.00 to −$1.85); for 2027 the estimate is −$1.75.
When does Acurx Pharmaceuticals report earnings?
Acurx Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens; the EPS estimate is $-0.45.
Does Acurx Pharmaceuticals usually beat earnings estimates?
Acurx Pharmaceuticals reported EPS at or above the analyst estimate in 9 of the last 12 quarters.